Literature DB >> 12663449

Single-chain antibody fragments derived from a human synthetic phage-display library bind thrombospondin and inhibit sickle cell adhesion.

Nicholas A Watkins1, Lily M Du, J Paul Scott, Willem H Ouwehand, Cheryl A Hillery.   

Abstract

The enhanced adhesion of sickle red blood cells (RBCs) to the vascular endothelium and subendothelial matrix likely plays a significant role in the pathogenesis of vaso-occlusion in sickle cell disease. Sickle RBCs have enhanced adhesion to the plasma and extracellular matrix protein thrombospondin-1 (TSP) under conditions of flow in vitro. In this study, we sought to develop antibodies that bind TSP from a highly diverse library of human single-chain Fv fragments (scFvs) displayed on filamentous phage. Following 3 rounds of phage selection of increasing stringency 6 unique scFvs that bound purified TSP by enzyme-linked immunosorbent assay were isolated. Using an in vitro flow adhesion assay, 3 of the 6 isolated scFvs inhibited the adhesion of sickle RBCs to immobilized TSP by more than 40% compared with control scFvs (P <.001). Furthermore, scFv TSP-A10 partially inhibited sickle RBC adhesion to activated endothelial cells (P <.005). Using TSP proteolytic fragments to map the binding site, we showed that 2 of the inhibitory scFvs bound an epitope in the calcium-binding domain or proximal cell-binding domain of TSP, providing evidence for the role of these domains in the adhesion of sickle RBCs to TSP. In summary, we have isolated a panel of scFvs that specifically bind to TSP and differentially inhibit sickle RBC adhesion to surface-bound TSP under flow conditions. These scFvs will be useful reagents for investigating the role of the calcium and cell-binding domains of TSP in sickle RBC adhesion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12663449     DOI: 10.1182/blood-2002-11-3497

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

1.  The analysis and quantification of a clonal B cell response in a hyperimmunized anti-D donor.

Authors:  S E Dohmen; O J H M Verhagen; S M de Groot; L M Stott; R C Aalberse; S J Urbaniak; C E van der Schoot
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

Review 2.  Demystified...recombinant antibodies.

Authors:  K A Smith; P N Nelson; P Warren; S J Astley; P G Murray; J Greenman
Journal:  J Clin Pathol       Date:  2004-09       Impact factor: 3.411

3.  Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain.

Authors:  Barbara Margosio; Marco Rusnati; Katiuscia Bonezzi; Blue-Leaf A Cordes; Douglas S Annis; Chiara Urbinati; Raffaella Giavazzi; Marco Presta; Domenico Ribatti; Deane F Mosher; Giulia Taraboletti
Journal:  Int J Biochem Cell Biol       Date:  2007-10-09       Impact factor: 5.085

4.  Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds.

Authors:  Giorgio Colombo; Barbara Margosio; Laura Ragona; Marco Neves; Silvia Bonifacio; Douglas S Annis; Matteo Stravalaci; Simona Tomaselli; Raffaella Giavazzi; Marco Rusnati; Marco Presta; Lucia Zetta; Deane F Mosher; Domenico Ribatti; Marco Gobbi; Giulia Taraboletti
Journal:  J Biol Chem       Date:  2010-01-07       Impact factor: 5.157

5.  Examination of Reticulocytosis among Chronically Transfused Children with Sickle Cell Anemia.

Authors:  Megha Kaushal; Colleen Byrnes; Zarir Khademian; Natalie Duncan; Naomi L C Luban; Jeffery L Miller; Ross M Fasano; Emily Riehm Meier
Journal:  PLoS One       Date:  2016-04-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.